Health Canada approves Puma Biotechnology’s (NASDAQ:PBYI) NERLYNX (neratinib) for the extended adjuvant treatment of women with early-stage hormone receptor-positive, HER2-overexpressed/amplified breast cancer within one year after completion of adjuvant therapy with Roche’s Herceptin (trastuzumab).
Licensee Knight Therapeutics will commercialize.
Shares are up 5% after hours.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.